In fact, the use of S100B as a screening tool, especially in mild traumatic brain injury, offered potential advantages over the use of GFAP; however, conclusive results have not been obtained, which is also attributed to analytical heterogeneity among laboratories, so a direct comparison across studies was unavailable. The gene discussed is S100B; the disease is injury.